You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 19, 2026

Details for New Drug Application (NDA): 088042


✉ Email this page to a colleague

« Back to Dashboard


NDA 088042 describes TRIDERM, which is a drug marketed by Crown Labs and is included in one NDA. It is available from ten suppliers. Additional details are available on the TRIDERM profile page.

The generic ingredient in TRIDERM is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy-seven suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
Summary for 088042
Tradename:TRIDERM
Applicant:Crown Labs
Ingredient:triamcinolone acetonide
Patents:0
Pharmacology for NDA: 088042
Mechanism of ActionCorticosteroid Hormone Receptor Agonists
Medical Subject Heading (MeSH) Categories for 088042
Anti-Inflammatory Agents
Glucocorticoids
Immunosuppressive Agents
Suppliers and Packaging for NDA: 088042
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TRIDERM triamcinolone acetonide CREAM;TOPICAL 088042 ANDA Crown Laboratories 0316-0165 0316-0165-15 1 TUBE in 1 CARTON (0316-0165-15) / 15 g in 1 TUBE
TRIDERM triamcinolone acetonide CREAM;TOPICAL 088042 ANDA Crown Laboratories 0316-0165 0316-0165-16 1 JAR in 1 CARTON (0316-0165-16) / 454 g in 1 JAR

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CREAM;TOPICALStrength0.1%
Approval Date:Mar 19, 1984TE:ATRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CREAM;TOPICALStrength0.025%
Approval Date:Mar 25, 2015TE:ATRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CREAM;TOPICALStrength0.5%
Approval Date:Mar 25, 2015TE:ATRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links